Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor vs clopidogrel in patients with peripheral artery disease
jRCT2080222014Phase 3
- Sponsor
- AstraZeneca
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ticagrelor in arteriosclerosis obliterans, cardiac morbidity, myocardial infarction (MI) and 1 more (2 arms), sponsored by AstraZeneca. Primary endpoint: Composite of cardiovascular death, myocardial infarction, and ischemic stroke.
02
Drugs
ticagrelor
03
Conditions
arteriosclerosis obliteranscardiac morbiditymyocardial infarction (MI)ischemic stroke
Beyond the preview
Go deeper on jRCT2080222014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222014.